Oral Rehydration Solution (ORS) Uses, Benefits, Dosage & Side Effects | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Electrolyte and Fluid Replacement
Subclass
Oral Rehydration Salts (WHO reduced osmolarity formula)
Speciality
Gastroenterology,
Schedule (India)
Not Scheduled (OTC)
Routes
Oral
Formulations
- Powder for oral solution: Sachets to prepare 1 litre of solution (WHO low-osmolarity formula – 245 mOsm/L)
- Ready-to-drink solution: 200 mL, 500 mL, 1 litre bottles
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Acute Diarrhoea – Prevention and Treatment of Dehydration
Assessment-based Rehydration Protocol:
| Dehydration Status | Clinical Features | Rehydration Dose | Maintenance After Each Stool |
|---|---|---|---|
| No dehydration (Plan A) | Well, alert; eyes normal; drinks normally; skin pinch retracts immediately | Not required | <2 yrs: 50–100 mL; 2–10 yrs: 100–200 mL; >10 yrs/adults: 200–500 mL |
| Some dehydration (Plan B) | Restless/irritable; sunken eyes; drinks eagerly; skin pinch retracts slowly (<2 sec) | 75 mL/kg over 4 hours | Reassess after 4 hours; continue maintenance |
| Severe dehydration (Plan C) | Lethargic/unconscious; very sunken eyes; drinks poorly; skin pinch retracts very slowly (>2 sec) | Start IV fluids first; switch to ORS once able to drink | Continue as per clinical response |
Clinical Notes:
- Reassess hydration status every 4 hours during rehydration phase
- ORS should be given by cup and spoon; avoid bottle feeding in infants
- Continue breastfeeding in infants throughout rehydration
- Freshly prepared ORS solution should be used within 24 hours
2. Cholera – Rehydration in Moderate Dehydration
| Parameter | Recommendation |
|---|---|
| Starting dose | 75–100 mL/kg over 4–6 hours |
| Titration | Not applicable |
| Usual maintenance dose | 200–500 mL after each watery stool |
| Maximum dose | As tolerated; guided by clinical hydration status |
Clinical Notes:
- In severe cholera with shock, initiate IV Ringer's Lactate first
- ORS serves as sole rehydration therapy in mild-to-moderate cases
- Zinc supplementation (as per ICMR/IAP) should accompany ORS in children
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Label Status | Evidence Basis |
|---|---|---|---|---|
| Mild dehydration due to heat exposure/exertional sweating | 500–1000 mL as tolerated | Short-term during exposure | OFF-LABEL | Indian public health protocols; occupational medicine practice |
| Post-exercise rehydration | 500 mL–1 L after exertion | Single episode | OFF-LABEL | Sports medicine practice; limited formal evidence |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Acute Diarrhoea – Prevention and Treatment of Dehydration
| Age Group | Weight | No Dehydration (Plan A) — Per Stool | Some Dehydration (Plan B) — Over 4 Hours |
|---|---|---|---|
| <6 months | <5 kg | 50 mL | 200–400 mL |
| 6 months–<2 years | 5–10 kg | 50–100 mL | 400–700 mL |
| 2–5 years | 10–19 kg | 100–200 mL | 700–900 mL |
| 5–10 years | 19–30 kg | 200 mL | 900–1400 mL |
| >10 years | >30 kg | 200–400 mL | 1500–2200 mL |
Minimum Age: No lower age limit; suitable from birth including neonates
Safety Monitoring:
- Administer with cup and spoon; avoid bottle feeding
- Monitor for signs of overhydration (periorbital oedema, respiratory distress)
- Assess hydration status every 1–2 hours during active rehydration
- If vomiting occurs, wait 10 minutes and resume at slower rate
- Continue breastfeeding during ORS therapy
Severe Dehydration Protocol:
- Initiate IV fluids (Ringer's Lactate) immediately
- Transition to ORS once patient can tolerate oral intake
- Specialist/facility-based management required
Secondary Indications — Paediatrics (Off-label, if any)
| Indication | Dose | Duration | Label Status | Evidence Basis |
|---|---|---|---|---|
| Mild exercise-induced dehydration | Same as acute diarrhoea protocols; 50–200 mL based on age | As needed | OFF-LABEL; Specialist guidance | Indian paediatric sports medicine practice |
| Vomiting-associated dehydration (without diarrhoea) | Small frequent sips; 5 mL every 1–2 minutes | Until vomiting resolves | OFF-LABEL | IAP clinical practice |
Age Restriction: No minimum age restriction; neonates may receive ORS under careful supervision to prevent aspiration.
Renal Adjustments
- Normal renal function: No adjustment required
- Chronic kidney disease (CKD): Use with caution; avoid large volumes without monitoring electrolytes
- Oliguria/Anuria: Avoid oral rehydration; specialist input mandatory
- Haemodialysis/Peritoneal dialysis: Volume intake must align with fluid restriction protocols; electrolyte monitoring essential
Hepatic adjustment
Contraindications
- Complete mechanical bowel obstruction
- Paralytic ileus
- Intractable vomiting precluding oral intake
- Severe dehydration with haemodynamic instability (requires IV fluids first)
- Altered consciousness with risk of aspiration
- Known hypersensitivity to any component of the formulation
Cautions'
- Hypernatraemic dehydration — rehydrate gradually over 12–24 hours to avoid cerebral oedema
- Glucose-galactose malabsorption — standard ORS may worsen diarrhoea
- Diabetes mellitus — glucose content may transiently affect glycaemic control; monitor blood glucose
- Heart failure — fluid overload risk; use controlled volumes with close monitoring
- Renal impairment — risk of electrolyte imbalance; monitor serum sodium and potassium
- Elderly patients — higher risk of aspiration and fluid overload
Pregnancy
| Parameter | Recommendation |
|---|---|
| Safety status | Safe for use in pregnancy |
| Preferred alternative | ORS is the preferred first-line therapy for diarrhoeal dehydration in pregnancy |
| When to use | Recommended for mild-to-moderate dehydration; IV fluids for severe dehydration |
| Monitoring | Monitor for fluid overload in pre-eclampsia or gestational hypertension |
Lactation
| Parameter | Recommendation |
|---|---|
| Compatibility | Fully compatible with breastfeeding |
| Drug levels in milk | Not applicable (oral electrolyte solution, not systemically absorbed) |
| Preferred alternative | None; ORS is first-line |
| Infant monitoring | Continue breastfeeding alongside ORS; monitor infant's hydration and feeding adequacy |
Elderly
- Starting dose: Begin with moderate volumes (100–200 mL at a time); assess tolerance
- Titration: Increase volume based on hydration response and tolerance
- Extra risks:
-
- Fluid overload in those with cardiac or renal comorbidities
- Aspiration risk if swallowing dysfunction or altered sensorium present
- Hyponatraemia or hypernatraemia if improper dilution
- Monitoring: Assess bowel sounds, respiratory status, fluid balance, and serum electrolytes
Major drug interactionsMajor drug interactions
None documented.
ORS is not systemically absorbed and does not undergo hepatic metabolism. No clinically significant pharmacokinetic or pharmacodynamic interactions are known.
Moderate drug interactions
| Interacting Drug | Interaction | Recommendation |
|---|---|---|
| Drugs with narrow therapeutic index (digoxin, lithium, phenytoin) | Diarrhoea-related altered gut transit may affect absorption | Monitor drug levels; adjust timing if feasible |
| Metformin | Diarrhoea may reduce absorption | Space doses 1–2 hours apart from ORS if possible |
| Oral antibiotics | Rapid gut transit may reduce bioavailability | Consider timing or parenteral alternatives in severe diarrhoea |
Common Adverse effects
- Abdominal bloating
- Mild nausea
- Flatulence
- Transient increase in stool frequency initially
- Unpleasant taste (in some formulations)
Serious Adverse effects
Rare; generally related to misuse or administration errors:
- Hypernatraemia — if solution prepared with insufficient water or excessive salt
- Fluid overload — in patients with cardiac or renal impairment; manifests as oedema, pulmonary congestion
- Aspiration pneumonia — in unconscious patients or infants given ORS via bottle
- Severe electrolyte disturbance — in renal failure without monitoring
Monitoring requirements'
| Timing | Parameters |
|---|---|
| Baseline | Assess dehydration severity clinically; weight; vital signs |
| During therapy (every 2–4 hours) | Hydration status (skin turgor, mucous membranes, urine output); weight; presence of vomiting |
| In high-risk patients | Serum sodium, potassium, glucose; fluid balance charting |
| After rehydration | Confirm resolution of dehydration signs; transition to maintenance and dietary recovery |
Brands in India
- Electral® (FDC)
- ORS WHO Formula (Cipla, Wallace, multiple generic manufacturers)
- ORSL® (flavoured variants)
- Walyte® (Wallace)
- Pedialyte® (Abbott) — paediatric formulation
- Enerzal ORS®
- Multiple government-supplied generic ORS sachets
Price range (INR)
| Formulation | Approximate Price | Notes |
|---|---|---|
| Powder sachets (for 1 L) | ₹5–15 per sachet | NLEM-regulated; widely available in government facilities |
| Ready-to-drink (200 mL) | ₹15–30 per bottle | Private retail |
| Ready-to-drink (500 mL–1 L) | ₹35–60 per bottle | Private retail |
NLEM Status: ORS is included in NLEM 2022; price-controlled formulation.
Clinical pearls
- Use only WHO-recommended reduced osmolarity ORS (245 mOsm/L); older high-osmolarity formulations are obsolete
- Freshly prepare ORS daily; discard unused solution after 24 hours
- Homemade sugar-salt solution (6 level teaspoons sugar + ½ level teaspoon salt in 1 litre water) may be used only if commercial ORS is unavailable — mixing accuracy is critical
- In infants: continue breastfeeding alongside ORS; it improves outcomes and reduces dehydration severity
- Zinc supplementation (10–20 mg/day for 10–14 days) is recommended alongside ORS in children <5 years with acute diarrhoea
- Severe dehydration or shock requires IV fluids (Ringer's Lactate) first — ORS is introduced once oral intake is tolerable
Version
RxIndia v1.0 — 28 May 2025
Reference
-
- NLEM 2022
- Indian Pharmacopoeia / National Formulary of India
- IAP Guidelines for Management of Acute Diarrhoea
- ICMR Guidelines on Diarrhoeal Disease Management
- WHO/UNICEF Joint Statement on Clinical Management of Acute Diarrhoea
- AIIMS Hospital Protocols
- API Textbook of Medicine
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.